Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response

HIGHLIGHTS

• who: Atte Valli and colleagues from the Molecular Immunology Group, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland have published the research work: Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response, in the Journal: (JOURNAL) of 19/04/2022
• what: The authors demonstrate here that while plasma MMP-1 levels were downregulated, levels of CCL2 or CXCL10 were not affected by 3-month tofacitinib 5mg twice daily plus csDMARD treatment in_vivo.

SUMMARY

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.